A new study from Israel suggests cannabinoids like THC and CBD could mitigate the multiplication of neuroblastoma, which is primarily a childhood disease. In the study, which was published in Current Oncology, researchers found CBD and THC were able to impede the growth of tumors by reducing their viability and invasiveness, and induce apoptosis. Of the two cannabinoids' anti-tumor effects, CBD was found to be more active.
Researchers used culture and animal models to test the effects of these cannabinoids on neuroblastoma. In the culture models, cells were treated with either cannabinoid or left untreated. In the animal models, mice were induced with tumors via subcutaneous injection, and were then injected with 20 mg/kg THC or 20 mg/kg CBD or left untreated for 14 days. Both models investigated the tumors by measuring and testing viability, cell cycle distribution, growth rate, cell invasiveness, and apoptotic cell death rate. Researchers conclude, “Our findings about the activity of CBD in [neuroblastoma] support and extend previous findings about the anti-tumor activities of CBD in other tumors and suggest that cannabis extracts enriched in CBD and not in THC could be suitable for the development of novel non-psychotropic therapeutic strategies in [neuroblastoma]."
This information has been provided by Medical Marijuana Inc. and approved by our Chief Medical Officer.